updat model follow compani result
featur continu strong perform companion anim busi
return growth livestock gross margin expans increas
compani financi target took ep estim base
higher revenu rais pt maintain
hold rate base view rel balanc risk/reward
stock continu view best-in-class anim health compani
increas revenu revenu
base primarili higher sale us companion
anim driven continu strong growth dermatolog franchis
simparica us livestock also rais gross margin assumpt
increas sg estim base compani
revis spend plan new ep
ep base recent multipl expans continu
strong fundament increas pt assum
stock trade ebitda previous
tr target
page
expens attribut non-control zoeti inc
page
expens attribut non-control zoeti inc
page
manufacturing/human changeu manufacturing/human oper revenueu manufacturing/human profitexist apoquel gross marginexist apoquel gross zoeti inc
page
manufacturing/human changeu manufacturing/human oper revenueu manufacturing/human profitexist apoquel gross marginexist apoquel gross zoeti inc
zoeti largest anim health compani world sale compani strong
perform sinc spun nr consist above-market revenu
growth signific margin expans well-diversifi revenu base geograph
across companion food anim segment compani expand veterinari
diagnost market acquisit abaxi
despit hold rate stock view best-in-class anim health compani
attract combin sustain organ growth diversifi portfolio low-risk strategi
cash-pay model leverag infrastructur expect base busi drive solid revenu
earn growth next year may supplement select busi
develop new launch said believ attribut larg understood
marketplac would prefer attract entri point thu rate share hold
valuat risk
pt assum stock trade ebitda similar
current multipl ebitda downsid risk includ lower growth livestock
companion segment lower growth abaxi lower sale key product apoquel cytopoint
simparica consolid custom and/or competitor global econom downturn advers
fx trend upsid risk includ higher growth livestock companion abaxi higher sale
apoquel cytopoint simparica greater contribut new product
compani mention note
gregg gilbert herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
